

CURRICULUM VITAE

ARKADIUSZ Z. DUDEK
United States

PROFESSIONAL ADDRESS

Arkadiusz Z. Dudek, MD, PhD
Medical Oncology
HealthPartners Cancer Care Center
Suite 1161 Mail Stop 11101G
640 Jackson Street, St. Paul, MN 55101
Tel: 651 254-3321
Fax: 651 254-3102
E-mail Address: Arkadiusz.Z.Dudek@HealthPartners.Com

IDENTIFYING INFORMATION

Education

Matura (Secondary School Certification) XIV Liceum Ogolnokształcące (Equivalent to High School). Warsaw, POLAND	1982
M.D. Medical University of Warsaw Warsaw, POLAND	1989
Ph.D. Military Medical Institute Medical Oncology Warsaw, POLAND	1998
Externship in Cardiology Groupe Hospitalier Pitie-Salpetriere, Paris, FRANCE	06/1988-09/1988
Internship in Internal Medicine Polyclinic Medical Center, Harrisburg, PA	07/1991-06/1992
Residency in Internal Medicine Polyclinic Medical Center, Harrisburg, PA	07/1992-06/1994
Visiting Residency in Gastroenterology The Milton S. Hershey Medical Center University Hospital, Penn State College of Medicine Hershey, PA	04/1993-05/1993
Clinical Fellowship: Bone Marrow Transplant Unit Johns Hopkins Hospital, Baltimore, MD	05/1993-06/1993
Visiting Residency in Rheumatology	

The Milton S. Hershey Medical Center Penn State College of Medicine, Hershey, PA	03/1994-04/1994
Fellowship: Hematology, Oncology and Transplantation University of Minnesota, Minneapolis, MN	07/1994-12/1997

Certifications, Licenses

2013 – Illinois State Board of Medical Examiners (active)
 2008 – American Board of Oncology, Recertification
 2008 – American Board of Hematology, Recertification
 2005 – American Board of Internal Medicine, Recertification
 1998 – American Board of Medical Oncology
 1997 – Fellowship in Hematology and Oncology Certification
 1997 – American Board of Hematology
 1994 – American Board of Internal Medicine
 1994 – Minnesota State Board of Medical Examiners (active)
 1994 – DEA registration (active)
 1991 – Pennsylvania State Board of Medical Examiners (inactive)

Academic Appointments

2013- Present	Professor of Medicine, University of Illinois at Chicago
2017- Present	Professor of Medicine, University of Minnesota
1997 – 2012	University of Minnesota, School of Medicine [Twin Cities]
2008 – 2012	Associate Professor of Medicine (non-tenured)
1998 – 2008	Assistant Professor of Medicine
1997 – 1998	Instructor of Medicine

Academic Administrative Appointments

2016 -2017	Senator, University of Illinois at Chicago, Member of the Senate Budget, Planning and Priorities Committee
2016	Co-Leader, Clinical Science Group University of Illinois Cancer Center
2013 – 2016	Director, Clinical Trials Office University of Illinois Cancer Center
2013 – 2016	Director, Phase 1 Unit University of Illinois Cancer Center
2013 – 2016	Leader, Cancer Target and Therapeutics Program Cancer Center, University of Illinois
2013 – 2016	Member, Executive Committee Cancer Center, University of Illinois
2012	Member, Executive Committee Masonic Cancer Center, University of Minnesota
2008 – 2012	Director, Solid Tumor Oncology, Cancer Experimental Therapeutics Initiative Masonic Cancer Center, University of Minnesota

2005 – 2008 Clinical Research Director, Division Hematology, Oncology and Transplantation
University of Minnesota

1998 – 2012 Co-Chair, Thoracic Oncology Program
University of Minnesota Comprehensive Cancer Center

Clinical/Hospital Appointments

2016 – Present Staff Physician
HealthPartners and Regions Cancer Care Center

2013 – 2017 Staff Physician
University of Illinois at Chicago

1997 – 2012 Staff Physician
University of Minnesota Medical Center, Fairview

Consulting Positions

2016 – Present TTC Oncology, Chief Medical Officer
2015 – 2016 Adhaere Pharmaceuticals, Inc, Chief Medical Officer
2014 – 2016 GeneSegues, Inc., Scientific Advisory Board
2014 – Present Martell Diagnostic Laboratories, Chairman of Medical Advisory Board
2014 – 2015 Vista Oncology, LLC, Board Member
2013 – Present Vanquish Oncology, Chairman of Clinical Advisory Board
2010 – 2018 IGF Oncology, Board Member
2007 – Present Biothera, Clinical Advisory Board Member
2005 – 2010 IGF Oncology, Consultant
2004 – 2010 Medisyn Technologies, Consultant

Current Membership and Offices in Professional Organizations

2013 – 2016 Member, University of Illinois Cancer Center Executive Committee
2008 – Present Member, International Association for the Study of Lung Cancer
2002 – Present Member, Fellow of American College of Physicians
1999 – 2012 Member, University of Minnesota Cancer Center
1998 – Present Member, European Society of Medical Oncology
1998 – 2009 Member, European Hematology Association
1998 – Present Member, American Association for Cancer Research
1998 – 2009 Member, American Association for the Advancement of Science
1997 – Present Member, American Society of Hematology
1997 – Present Member, American Society of Clinical Oncology

Visiting Professorships or Visiting Scholar Positions

Name of university/college/institute; department; dates; focus

HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT, AND SERVICE

University of Illinois

2014 Hematology and Oncology Fellowship Program:
Mentor Award

University of Minnesota

2010 Hematology, Oncology, and Transplantation Fellowship Program:
Outstanding Academic Mentor Award
2005 - 2007 University of Minnesota Cancer Center Clinical Scholar Award
2005 University of Minnesota, Department of Medicine, Clinical Excellence Award
2004 University of Minnesota Cancer Center Award of Recognition

External Sources

2011 Champions of Care Honor, Fairview Foundation
2006 - 2009 American Medical Association: Physicians' Recognition Award
1999 Fellow American College of Physicians

RESEARCH AND SCHOLARSHIP

Grants and Contracts

National Clinical Research

Investigator status: Study Chair
External Agency: Cancer and Leukemia Group B
Project title: CALGB 30901: Randomized Phase II Study of Maintenance Pemetrexed vs
Observation for Patients with Malignant Mesothelioma without Progression after First-Line
Chemotherapy
Dates: 2009 - current
Direct costs/year: N/A
% Funded salary support: N/A

Investigator status: Study Chair
External Agency: Cancer and Leukemia Group B
Project title: CALGB 30601: A Phase II study of Dasatinib (NSC #732517, IND #73969) in
patients with previously treated Malignant Mesothelioma
Dates: 2006 - 2011
Direct costs/year: N/A
% Funded salary support: N/A

Clinical Research Investigator Initiated Grants

Investigator status: Principal investigator
External Agency: Big Ten Cancer Research Consortium
Project title: Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-
Treated Mesothelioma: Big Ten Cancer Research Consortium BTCRC-LUN15-025.
Dates: 2016 - ongoing
Direct costs/year: \$967,000
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Big Ten Cancer Research Consortium
Project title: Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3475 in Combination
with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer
Research Consortium BTCRC-GU14-003.
Dates: 2015 - ongoing
Direct costs/year: \$999,342

% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Millennium, The Takeda Oncology Company
Project title: Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors.
Dates: 2013 - ongoing
Direct costs/year: \$545,762
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Bristol-Myers Squibb and GlaxoSmithKline Pharmaceuticals
Project title: 2009LS001. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumor. IND Number: 106653.
Dates: 2009 -2012
Direct costs/year: \$ 411,107
% Funded salary support: 5%

Clinical Research Industry Sponsored Grants

Investigator status: Principal investigator
External Agency: Argos Therapeutics, Inc.
Project title: AGS-003-007: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Dates: 6/2013-6/2018
Direct costs/year: \$ 142,493,
% Funded salary support: 1%

Investigator status: Principal investigator
External Agency: NewLink Genetics & Dendreon Corporation
Project title: PRO-01: A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate
Dates: 7/2013-7/2016
Direct costs: \$ 163,103
% Funded salary support: 1%

Grants –Basic Research

Investigator status: Principal investigator
External Agency: Randy Shaver Cancer Research and Community Fund
Project title: CSPG4 activation of PI3K/mTOR pathway in melanoma
Dates: 2011 - 2012
Direct costs/year: \$22,224
% Funded salary support: 1%

Investigator status: Principal investigator
External Agency: Randy Shaver Cancer Research and Community Fund
Project title: Melanoma Proteoglycan Function in Melanoma with Mutated BRAF
Dates: 2010 - 2011

Direct costs/year: \$ 25,178
% Funded salary support: 10%

Investigator status: Principal investigator
External Agency: Susan G. Komen Breast Cancer Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2006 - 2008
Direct costs/year: \$200,000
% Funded salary support: 10%

Investigator status: Principal investigator
External Agency: Eli Lilly and Company
Project title: Preclinical study of protein kinase C inhibitor, enzaustarin in combination with radiation
Dates: 2006
Direct costs/year: \$30,000
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Pardee Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2005
Direct costs/year: \$100,000
% Funded salary support: 5%

Investigator status: Principal investigator
External Agency: Susan G. Komen Breast Cancer Foundation
Project title: Blood Outgrowth Endothelial Cells Based Cancer Gene Therapy
Dates: 2002 - 2004
Direct costs/year: \$67,000
% Funded salary support: 10%

University Sources

Clinical Research Investigator Initiated Grants

Investigator status: Principal investigator
External Agency: Masonic Cancer Center
Project title: 2006LS046. A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma. IND # 10156.
Dates: 2006 - 2011
Direct costs: \$ 96,813

Investigator status: Co-investigator
Agency: SP3 proposal, Masonic Cancer Center, University of Minnesota
Project title: Genomic Signatures for Colorectal Cancer
Dates: 2012 - 2013
Direct costs: \$ 240,000
% Funded salary support: (2% unpaid)

Investigator status: Principal investigator

Agency: University of Minnesota Grant in Aid of Research, Artistry, and Scholarship

Project title: CSPG4 activation of PI3K/mTOR pathway in melanoma

Dates: 1/2012 - 6/30/2013

Direct costs: \$ 18,224

% Funded salary support: (1% unpaid)

Investigational New Drug Application First in Human Trials

IND 109843	Super Compound Interferon-rSIFN-co
IND 116840	IGF-MTX conjugate
IND 120544	Procaspase-Activating Compound-1 (PAC-1)

Publications

Impact Analytics

<i>h</i> -Index	Total Publications	First/Last Author Publications	Total Citations
24	122	80 (30/50)	2262

Peer-Reviewed Publications

- Shah HA, Fischer JH, Venepalli NK, Danciu OC, Christian S, Russell MJ, Liu LC, Zacny JP, Dudek AZ. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. *Am J Clin Oncol*. 2019 May;42(5):413-420. doi: 10.1097/COC.0000000000000543. PMID: 30973373
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.997 Citation Index:
- Schmidt TM, Liu LI, Abraham IE, Uy AB, **Dudek AZ**. Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. *Anticancer Res*. 2018 Jul;38(7):4027-4034. doi: 10.21873/anticancer.12691. PMID: 29970527
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: -
- Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, Myers TG, **Dudek AZ**, Druey KM. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). *J Leukoc Biol*. 2018 Jan 23. doi: 10.1002/JLB.5A0817-324R.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review
Impact Factor: 4.018 Citation Index: -
- Feldman LE, Pasquinelli M, Alban J, **Dudek AZ**, Winn R, Watson K, Menchaca MG, Koshy M, Kovitz K. PS01.11: Comparison of Initial (T0) Screens in UI Health's Minority-Based Lung Cancer Screening Program to that of the National Lung Screening Trial (NLST): Topic:

- Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S275-S276. doi: 10.1016/j.jtho.2016.09.046. Epub 2016 Oct 28. PMID: 27969478
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review
 Impact Factor: 6.595 Citation Index: -
5. Bhattacharyya S, Feferman L, Terai K, **Dudek AZ**, Tobacman JK. Decline in arylsulfatase B leads to increased invasiveness of melanoma cells. Oncotarget. 2017 Jan 17;8(3):4169-4180. doi: 10.18632/oncotarget.13751 PMID: 27926479
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.168 Citation Index: -
 6. **Dudek AZ**. Management of Resistance to EGFR TKI-Targeted Therapy of Lung Cancer: Lessons in Monitoring Cancer Evolution. Oncology (Williston Park). 2016 Jul 15;30(7). pii: 217974. URL: <http://www.cancernetwork.com/oncology-journal/management-resistance-egfr-tki-targeted-therapy-lung-cancer-lessons-monitoring-cancer-evolution>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.152 Citation Index: -
 7. Keshtgarpour M, Tan WS, Zwanziger J, Awadalla S, Langi FG, **Dudek AZ**. Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer. Anticancer Res. 2016 Apr;36(4):1759-65.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.895 Citation Index: -
 8. Saba R, Alsayed A, Zacny JP, **Dudek AZ**. The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy. Int J Breast Cancer. 2016;2016:9768183. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752991/>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: unknown Citation Index: -
 9. Ganesan C, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, **Dudek AZ**. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. Am J Clin Oncol. 2016 Jun;39(3):280-7.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.997 Citation Index: -
 10. Sek AC, Xie Z, Terai K, Long LM, Nelson C, **Dudek AZ**, Druet KM. Endothelial Expression of Endothelin Receptor A in the Systemic Capillary Leak Syndrome. PLoS One. 2015;10(7):e0133266. doi: 10.1371/journal.pone.0133266. eCollection 2015. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503617/>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.057 Citation Index: 2
 11. Amin A, **Dudek AZ**, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404644/>

- ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: unknown Citation Index: 14
12. Ojevwe FO, Ojevwe CD, Zacny JP, **Dudek AZ**, Lin A, Kohlitz P. Treatment of Multiple Unresectable Basal Cell Carcinomas from Gorlin-Goltz Syndrome: a Case Report. *Anticancer Res.* 2015;35(3):1777-81.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: 1
13. Javaid S, Terai K, **Dudek AZ**. Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways. *Anticancer Res.* 2015;35(3):1279-84.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: -
14. Kim C, Economou S, Amatruda TT, Martin JC, **Dudek AZ**. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. *Anticancer Res.* 2015;35(1):301-9.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: -
15. Gummadi T1, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, **Dudek AZ**. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. *Melanoma Res.* 2015;25(1):75-9.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.219 Citation Index: 2
16. Reddy SP, Natarajan V, **Dudek AZ**. MARCKS Is Marked in Combating Lung Cancer Growth and Acquired Resistance. *Am J Respir Crit Care Med.* 2014;190(10):1084-6. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299642/>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 13.118 Citation Index: 1
17. Litvan J, Aghazarian M, Wiley E, Guleria S, **Dudek AZ**. Primary peritoneal angiosarcoma: a case report. *Anticancer Res.* 2014;34(9):5001-6.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: -
18. Masri SC, Misselt AJ, **Dudek A**, Konety SH. Radiation recall reaction causing cardiotoxicity. *J Cardiovasc Magn Reson.* 2014;16(1):25. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023176/>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 5.752 Citation Index: not yet published
19. Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, **Dudek AZ**. Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. *Amer J Clin Oncol.* 2014;37(3):261-5.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.997 Citation Index: -

20. **Dudek AZ**, Kumar P, Thaw SS, Cao Q, Pawloski P, Larson T. Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC. *Am J Clin Oncol*. 2014;37(2):140-3.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.997 Citation Index: -
21. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team (**AZ Dudek**). Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2014;15(1):59-68.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor 26.509 Citation Index: 4
22. **Dudek AZ**, Kumar P, H Thaw SS, Cao Q, Pawloski P, Larson T. Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC. *Am J Clin Oncol*. 2014;37(2):140-3.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor 2.997 Citation Index: 2
23. Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, **Dudek AZ**, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. *Br J Cancer* 2014;110(2):304-12. URL:<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899768/>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor 5.569 Citation Index: 5
18. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, **Dudek AZ**. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. *Anticancer Res*. 2014 May;34(5):2405-11.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor 1.895 Citation Index: 10
24. Litterman AJ, **Dudek AZ**, Largaespada DA. Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. *Oncoimmunology*. 2013 Oct 1;2(10):e26294. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827073/>
ROLE: Defining Intellectual content. Manuscript editing, Manuscript review.
Impact Factor 7.644 Citation Index: 3
25. Zwolak P, **Dudek AZ**. Antineoplastic activity of zoledronic acid and denosumab *Anticancer Res*. 2013 Aug;33(8):2981-8.
ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review, Corresponding Author.
Impact Factor 1.895 Citation Index: 4
26. Powell SF, Beitinjaneh A, Tessema M, Bliss RL, Kratzke RA, Leach J, **Dudek AZ**. Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-small-cell Lung Cancer. *Clin Lung Cancer*. 2013 Sep;14(5):495-501. pii: S1525-7304(13)00077-6. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524809/> 10.1016/j.clcc.2013.04.009.
ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review, Corresponding Author.
Impact Factor 3.030 Citation Index: 2

27. Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, **Dudek AZ**, Salazar AM, Ohlfest JR. Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy. *J Immunol.* 2013 Jun 15;190(12):6259-68. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23686484>
ROLE: Manuscript editing, Manuscript review.
Impact Factor 4.985 Citation Index: 20
28. Sreenivasan V, **Dudek AZ**. Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam . *Case Rep Oncol.* 2013 Jan;6(1):78-83. doi: 10.1159/000346932. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573788/>
ROLE: Data acquisition, Manuscript editing, Manuscript review.
Impact Factor 0.15 (SJR) Citation Index: -
29. Endrizzi B, Ahmed RL, Ray T, **Dudek A**, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. *Dermatol Surg.* 2013 Apr;39(4):634-45. doi: 10.1111/dsu.12049.
ROLE: Manuscript editing, Manuscript review.
Impact Factor 1.936 Citation Index: -
30. Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, **Dudek AZ**, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. *Invest New Drugs.* 2013 Aug;31(4):1001-7.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
Impact Factor 3.281 Citation Index: 9
31. **Dudek AZ**, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF. Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors. *Clin Genitourin Cancer.* 2013 Jun;11(2):155-60. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467684/> 10.1016/j.clgc.2012.11.001.
ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.599 Citation Index: 9
32. Mittapalli RK, Vaidhyanathan S, **Dudek AZ**, Elmquist WF. Mechanisms Limiting Distribution of the BRAFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. *J Pharmacol Exp Ther.* 2013 Mar;344(3):655-64. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23249624>
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.760 Citation Index: 41
33. Mitra AK, Kirstein MN, Khatri A, Skubitz KM, **Dudek AZ**, Greeno EW, Kratzke RA, Lamba JK. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. *Pharmacogenomics.* 2012 Jul;13(9):1009-21.
ROLE: Conducted experimental studies, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.710 Citation Index: 10
34. Thumbigere-Math V, Tu L, Huckabay S, **Dudek AZ**, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R. A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. *Am J Clin Oncol.* 2012 Aug;35 (4):386-392.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.

- Impact Factor: 2.997 Citation Index: 17
35. Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, **Dudek AZ**, Latz JE, Shi P, Wakelee HA A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. *Lung Cancer* 2012 Oct;78(1):57-62. URL: [http://www.lungcancerjournal.info/article/S0169-5002\(12\)00384-4/fulltext](http://www.lungcancerjournal.info/article/S0169-5002(12)00384-4/fulltext)
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.767 Citation Index: -
36. Yoseph B, Chi M, Truskinovsky AM, **Dudek AZ**. Large-cell neuroendocrine carcinoma of the cervix. *Rare Tumors*. 2012 Jan 2;4(1):e18. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325745/>
ROLE: Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: unknown Citation Index: -
37. Chi M, **Dudek AZ**, Wind KP. Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors. *Onkologie*. 2012;35(4):210-4.
ROLE: Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.522 Citation Index: 1
38. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, **Dudek AZ**, Olyae MS, Esfandyari T, Farassati F. Inhibition of mesothelin as a novel strategy for targeting cancer cells. *PLoS One*. 2012;7(4):e33214. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317639/>
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
Impact Factor: 3.057 Citation Index: 15
39. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, **Dudek AZ**, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol*. 2012 May;13(5):539-48.
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 26.509 Citation Index: 179
40. **Dudek AZ**, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B. Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report. *J Thorac Oncol*. 2012 Apr;7(4):755-9. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308128/>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 5.040 Citation Index: 18
41. Wang H, Cao Q, **Dudek AZ**. Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy. *Anticancer Res*. 2012 Mar;32(3):1027-31.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: 15
42. Liu SV, Truskinovsky AM, **Dudek AZ**, Ramanathan RK. Metastatic Clear Cell Adenocarcinoma of the Urethra in a Male Patient: Report of a Case. *Clin Genitourin Cancer*. 2012 Mar;10(1):47-9.

- ROLE: Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 2.599 Citation Index: 1
43. Jahan T, Gu L, Kratzke R, **Dudek A**, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). *Lung Cancer*. 2012 Jun;76(3):393-6.
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.767 Citation Index: -
44. Zhang H, Li W, Franklin MJ, **Dudek AZ**. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. *Anticancer Res*. 2011 Nov;31(11):3945-52.
ROLE: Guarantor of integrity of entire study, Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: 19
45. Ready NE, **Dudek AZ**, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. *J Clin Oncol*. 2011 Nov 20;29(33):4436-41. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221525/>
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 20.982 Citation Index: 35
46. Price MA, Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, **Dudek AZ**, Turley EA, McCarthy JB. CSPG4, a Potential Therapeutic Target, Facilitates Malignant Progression of Melanoma. *Pigment Cell Melanoma Res*. 2011 Dec;24(6):1148-57. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426219/>
ROLE: Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.619 Citation Index: 29
47. Chi M, **Dudek AZ**. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. *Melanoma Res*. 2011 Jun;21(3):165-74.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.219 Citation Index: 14
48. Jasinski P, Zwolak P, Terai K, Vogel RI, Borja-Cacho D, **Dudek AZ**. MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. *Anticancer Res*. 2011 Apr;31(4):1181-7.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.895 Citation Index: 2
49. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, **Dudek A**, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. *Pigment Cell Melanoma Res*. 2011 Apr;24(2):386-9. doi: 10.1111/j.1755-148X.2011.00835.x.
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.619 Citation Index: 3
50. Czech W, Dzwiniel W, Goryczka S, Arodz T, **Dudek AZ**. Exploring Complex Networks with Graph Investigator Research Application. *Computing and Informatics*. 2011;30(2):381-410.

- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 0.524 Citation Index: 9
51. Jasinski P, Zwolak P, Isaksson Vogel R, Bodempudi V, Terai K, Galvez J, Land D, **Dudek AZ**. MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. *Invest New Drugs*. 2011 Oct;29(5):846-52.
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 3.281 Citation Index: 6
52. Bommakanti SV, **Dudek AZ**, Khatri A, Kirstein MN, Gada PD. Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors. *Am J Clin Oncol*. 2011 Dec;34(6):597-602.
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 2.997 Citation Index: 3
53. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, **Dudek AZ**. Metanephric adenoma of the kidney: an unusual diagnostic challenge. *Rare Tumors*. 2010 Jun 30;2(2):e38. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994510/>
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: unknown Citation Index: unknown
54. Kluger HM, **Dudek AZ**, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. *Cancer*. 2011 May 15;117(10):2202-8. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116034/>
- ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 5.649 Citation Index: 54
55. **Dudek AZ**. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. *Transl Res*. 2010 Sep;156(3):136-46.
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 4.557 Citation Index: 23
56. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, **Dudek AZ**. Capecitabine for skin cancer prevention in solid organ transplant recipients. *Clin Transplant*. 2011 Jul-Aug;25(4):541-8.. doi: 10.1111/j.1399-0012.2010.01348.x.
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
- Impact Factor: 1.844 Citation Index: 19
57. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, **Dudek AZ**. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. *Clin Lung Cancer*. 2010 Sep 1;11(5):E1-4.
- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*

- Impact Factor: 3.030 Citation Index: 22
58. Powell SF, **Dudek AZ**. Treatment of melanoma-associated retinopathy. *Curr Treat Options Neurol*. 2010 Jan;12(1):54-63.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.150 Citation Index: 7
59. **Dudek AZ**, Gupta K, Ramakrishnan S, Mukhopadhyay D. Tumor Angiogenesis. *J Oncol* Volume 2010 (2010), Article ID 761671, doi:10.1155/2010/761671. Editorial. *ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.*
 Impact Factor: - Citation Index: -
60. Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K, Hebbel RP, **Dudek AZ**. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. *Cancer Gene Therapy* 2010 Dec;17(12):855-63. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944849/>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.532 Citation Index: 8
61. Antony GK, **Dudek AZ**. Interleukin 2 in Cancer Therapy. *Curr Med Chem*. 2010;17(29):3297-302.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.455 Citation Index: 33
62. Raza A, Franklin MJ, **Dudek AZ**. Pericytes and vessel maturation during tumor angiogenesis and metastasis. *Am J Hematol*. 2010 Aug; 85(8):593-8. URL: <http://onlinelibrary.wiley.com/doi/10.1002/ajh.21745/full>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.000 Citation Index: 96
63. Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, **Dudek AZ**, Vokes EE, Green MR; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. *J Thorac Oncol*. 2010 Jun;5(6):810-7. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505667/>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.040 Citation Index: 9
64. Antony GK, Bertino E, Franklin M, Otterson GA, **Dudek AZ**. Small cell lung cancer in never smokers: report of two cases. *J Thorac Oncol*. 2010 May;5(5):747-8. URL: [http://www.jto.org/article/S1556-0864\(15\)32153-5/fulltext](http://www.jto.org/article/S1556-0864(15)32153-5/fulltext)
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.040 Citation Index: 7

65. **Dudek AZ**, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. *Anticancer Res.* 2010 Mar;30(3):987-92.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.895 Citation Index: 11
66. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, **Dudek AZ**, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. *J Clin Oncol.* 2010 May 20;28(15):2598-603.
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 20.982 Citation Index: 65
67. **Dudek AZ**, Murthaiah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. *Acta Oncol.* 2010;49(1):101-4.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.730 Citation Index: 4
68. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, **Dudek AZ**, Fisher J, Cheng EY. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. *J Bone Joint Surg Am.* 2010 Jan;92(1):162-8.
ROLE: Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.163 Citation Index: 20
69. Kamada P, **Dudek AZ**. Sorafenib Therapy for Metastatic Renal Carcinoma in Patients with Low Cardiac Ejection Fraction: Report of Two Cases and Literature Review. *Cancer Invest.* 2010 Jun;28(5):501-4.
ROLE: Guarantor of integrity of entire study, Developed Study design, Defined intellectual content, Conducted literature research Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.231 Citation Index: 3
70. Powell S, **Dudek AZ**. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. *Anticancer Res.* 2009 Oct;29(10):4189-93. URL: <http://ar.iiarjournals.org/content/29/10/4189.long>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.895 Citation Index: 11
71. Jasinski P, Zwolak P, Terai K, Borja-Cacho D, **Dudek AZ**. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis. *Invest New Drugs.* 2011 Feb;29(1):33-40.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.281 Citation Index: 4
72. Oh S, Stish BJ, Sachdev D, Chen H, **Dudek AZ**, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

- Clin Cancer Res. 2009 Oct 1;15(19):6137-47. Epub 2009 Sep 29. URL:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756320/>
ROLE: Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 8.738 Citation Index: 23
73. Stish BJ, Oh S, Chen H, **Dudek AZ**, Kratzke RA, Valleria DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer. 2009 Oct 6;101(7):1114-23. URL:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768099/>
ROLE: Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.569 Citation Index: 19
74. Spector E, Franklin MJ, Truskinovsky AM, **Dudek AZ**. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol. 2009 Aug 26:1-3.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.730 Citation Index: -
75. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, **Dudek AZ**, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009 Sep;67(9):1904-13.
ROLE: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.631 Citation Index: 34
76. **Dudek AZ**, Lesniewski-Kmak K, Larson T, Dragev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. J Thorac Oncol. 2009 Aug;4(8):969-75. URL: [http://www.jto.org/article/S1556-0864\(15\)32446-1/fulltext](http://www.jto.org/article/S1556-0864(15)32446-1/fulltext)
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.040 Citation Index: 6
77. Wcisło R, Dzwinel W, Yuen DA, **Dudek AZ**. A 3-D model of tumor progression based on complex automata driven by particle dynamics. J Mol Model. 2009 Dec;15(12):1517-39.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Manuscript editing, Manuscript review.
 Impact Factor: 1.438 Citation Index: 13
78. McTavish H, Griffin RJ, Terai K, **Dudek AZ**. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res. 2009 Jun;153(6):275-82.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 4.557 Citation Index: 5
79. Murthaiah P, Truskinovsky AM, Shah S, **Dudek AZ**. Collision Tumor versus Multiphenotypic Differentiation: A Case of Carcinoma with Features of Colonic and Lung Primary Tumors. Anticancer Res. 2009 May; 29(5):1495-7. URL:
<http://ar.iiarjournals.org/content/29/5/1495.long>
ROLE: Guarantor of integrity of entire study, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.895 Citation Index: 6

80. Powell SF, **Dudek AZ**. Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. *Pharmgenomics Pers Med*. 2009 2: 21–37.
ROLE: Guarantor of integrity of entire study, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: unknown Citation Index: -
81. Bodempudi V, Yamoutpour F, Pan W, **Dudek AZ**, Esfandyari T, Piedra M, Babovick D, Woo RA, Mautner VF, Kluwe L, Clapp DW, Devries GH, Thomas SL, Kurtz A, Parada LF, Farassati F. Ral overactivation in malignant peripheral nerve sheath tumors. *Mol Cell Biol*. 2009 Jul;29(14):3964-74. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704746/>
ROLE: Manuscript editing, Manuscript review.
 Impact Factor: 4.427 Citation Index: 20
82. **Dudek AZ**, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. *Br J Cancer*. 2009 May 5;100(9):1379-84. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694419/>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.569 Citation Index: 28
83. Leone JP, **Dudek AZ**. Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. *Anticancer Res*. 2008 Nov-Dec;28(6B):3937-9. URL: <http://ar.iijournals.org/content/28/6B/3937.long>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 1.895 Citation Index: 4
84. **Dudek AZ**, Zolnierek J, Dham A, Lindgren BR, and Szczylik C. Sequential Therapy with Sorafenib and Sunitinib in Renal Cell Carcinoma. *Cancer* 2009 Jan 1;115(1):161-7. URL: <http://onlinelibrary.wiley.com/doi/10.1002/cncr.24009/full>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.649 Citation Index: 116
85. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, **Dudek AZ**, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. *Mol Cancer Ther*. 2008 Nov;7(11):3586-97.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
 Impact Factor: 5.579 Citation Index: 11
86. Jasinski P, Zwolak P, Terai K, **Dudek AZ**. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. *Transl Res*. 2008 Nov;152(5):203-12. Epub 2008 Oct 11.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 4.557 Citation Index: 14
87. **Dudek AZ**, Nguyen S. Safety of Nab-paclitaxel plus Sunitinib: Analysis of Three Cases. *Anticancer Res* 2008 Sep-Oct;28(5B):3099-105. URL: <http://ar.iijournals.org/content/28/5B/3099.full.pdf>

- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 1.895 Citation Index: 2
88. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group (**Dudek AZ**). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. *J Natl Cancer Inst.* 2008 Oct 15;100(20):1454-63.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
Impact Factor: 13.757 Citation Index: -
89. Zwolak P, Jasinski P, Terai K, Gallus N, Ericson ME., Clohisy DR., **Dudek AZ**. Addition of receptor tyrosine kinase inhibitor to radiation increases tumor control in an orthotopic murine model of breast cancer metastasis in bone. *Eur J Cancer.* 2008 Nov;44(16):2506-17. *ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 6.163 Citation Index: 24
90. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group (**Dudek AZ**). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet.* 2008 Aug 9;372(9637):449-56.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
Impact Factor: 44.002 Citation Index: 649
91. Whitson BA, Groth SS, Andrade RS, Garrett L, **Dudek AZ**, Jessurun J, Maddaus MA. Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodes. *J Thorac Cardiovasc Surg.* 2008 May;135(5):1022-8. URL: [http://www.jtcvsonline.org/article/S0022-5223\(08\)00037-8/fulltext](http://www.jtcvsonline.org/article/S0022-5223(08)00037-8/fulltext)
ROLE Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.494 Citation Index: 4
92. Jasinski P, Terai K, Zwolak P, **Dudek AZ**. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. *Eur J Cancer.* 2008 Jun;44(9):1315-22.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 6.163 Citation Index: 7
93. **Dudek AZ**, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. *Am J Clin Oncol.* 2008 Apr;31(2):173-81.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 2.997 Citation Index: 15
94. **Dudek AZ**, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. *J Thorac Oncol.* 2008 Apr;3(4):394-399. URL: [http://www.jto.org/article/S1556-0864\(15\)31437-4/fulltext](http://www.jto.org/article/S1556-0864(15)31437-4/fulltext)

- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 5.040 Citation Index: 15
95. **Dudek AZ**, Chereddy S, Nguyen S, Wagner JE, Maddaus M.J Thorac Oncol. Neoadjuvant Chemotherapy with Reduced-Dose Carboplatin and Gemcitabine for Non-small Cell Lung Cancer in a Patient with Fanconi Anemia. J Thor Oncol. 2008 Apr;3(4):447-450. URL: [http://www.jto.org/article/S1556-0864\(15\)31448-9/fulltext](http://www.jto.org/article/S1556-0864(15)31448-9/fulltext)
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 5.040 Citation Index: 3
96. Nguyen S, Franklin M, **Dudek AZ**. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res. 2008 Apr;151(4):194-6.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.557 Citation Index: 2
97. Subhadra C, **Dudek AZ**, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin J Neuroophthalmol. 2008 Mar;28(1):23-6.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.576 Citation Index: 14
98. Mulamalla K, Truskinovsky AM, **Dudek AZ**. Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008 March 151(3):129-33.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.557 Citation Index: 15
99. Dham A, Truskinovsky A.M, **Dudek AZ**. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: A Case Report. J Thorac Oncol. 2008 Jan;3(1):94-7. URL: [http://www.jto.org/article/S1556-0864\(15\)31208-9/fulltext](http://www.jto.org/article/S1556-0864(15)31208-9/fulltext) *ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 5.040 Citation Index: 6
100. Arodz T, **Dudek AZ**. Multivariate Modeling and Analysis in Drug Discovery. Current Computer –Aided Drug Design, 2007, 3, 240-7.
ROLE: Guarantor of integrity of entire study, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.155 Citation Index: -
101. **Dudek AZ**, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A a novel systemic Toll-Like Receptor 7 agonist to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007 December 1;13 (23):7119-25. URL: <http://clincancerres.aacrjournals.org/content/13/23/7119.long>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 8.738 Citation Index: 53

102. Jasinski P, Welsh B, Galves J, Land D, Zwolak, P, Ghandi L, Terai K, **Dudek AZ**. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. *Invest New Drugs*. 2008 Jun;26(3):223-32.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.281 Citation Index: 32
103. Zwolak P, **Dudek AZ**, Bodempudi V, Nguyen J, Hebbel RP, Gallus NJ, Ericson ME, Goblirsch MJ, and Clohisy DR,. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. *Int J Cancer*. 2008 Feb 1;122(3):681-8. URL:
<http://onlinelibrary.wiley.com/doi/10.1002/ijc.23157/full>
ROLE: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.531 Citation Index: 11
104. **Dudek AZ**, Larson T, Keshtgarpour M, Kumar P. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. *Am J Clin Oncol*. 2007 October; 30(5):481-6.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 2.997 Citation Index: 2
105. **Dudek AZ**, Zwolak P, Jasinski P, Terai Kaoru, Gallus NJ, Ericson ME, Farassati F. Protein kinase C- β inhibitor enzastaurin (LY317615.HCl) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. *Invest New Drugs*. 2007, August 6; 26(1):13-24. DOI: 10.1007/s10637-007-9079-y.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 3.281 Citation Index: 16
106. **Dudek AZ**, Bodempudi V, Milbauer L, Griffin RJ, Hebbel RP. Systemic Inhibition of Tumor Angiogenesis by endothelial cell-based gene therapy. *Br J Cancer*. 2007 August; 97(4):513-22. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360342/>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
 Impact Factor: 5.569 Citation Index: 21
107. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, **Dudek AZ**, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. *J Clin Oncol*. 2007 May 20;25(15):2078-85.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
 Impact Factor: 20.982 Citation Index: 47
108. Mullamala K, Truskinovsky AM, **Dudek AZ**. Case report: renal metastasis of pulmonary blastoma responds to sorafenib. *J Thor Oncol*. 2007 April;2 (4); 44-7. URL:
[http://www.jto.org/article/S1556-0864\(15\)30080-0/fulltext](http://www.jto.org/article/S1556-0864(15)30080-0/fulltext)

- ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.*
Impact Factor: 5.040 Citation Index: 5
109. Keshtgarpour M, **Dudek AZ**. SU-011248, a Vascular Endothelial Growth Factor Receptor- Tyrosine Kinase Inhibitor, controls chronic psoriasis. *Transl Res.* 2007 March;149(3): 103-106.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.557 Citation Index: 13
110. Kirstein MN, Moore MM, **Dudek AZ**. Review of selected Patents for Cancer Therapy Targeting Tumor Angiogenesis. *Recent Patents on Anti-Cancer Drug Discovery.* 2006 June;1(2):153-61.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.533 Citation Index: 5
111. **Dudek AZ**, Arodz T, Galvez, J. Computational Methods in Developing Quantitative Structure-Activity Relationships (QSAR): A Review. *Comb Chem High Throughput Screen.* 2006 March ;9(3):213-28.
ROLE: Guarantor of integrity of entire study, Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 1.041 Citation Index: 149
112. **Dudek AZ**, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. *Curr Opin Oncol.* 2006 March;18(2):115-9.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.614 Citation Index: 8
113. Arodz T, Yuen DA, **Dudek AZ**. Ensemble of Linear Models for Predicting Drug Properties. *J Chem Inf Model.* 2006 Jan-March;46(1):416-23.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.657 Citation Index: 18
114. **Dudek AZ**, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. *Lung Cancer.* 2006 Jan;51(1):89-96.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 3.172 Citation Index: 37
115. **Dudek AZ**, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment responses and survival. *Cancer Invest.* 2005;23(3):193-200.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.

- Impact Factor: 2.231 Citation Index: 70
116. Miller JS, Curtsinger J, Berthold M, Malvey K, Bliss RL, Le CT, Fautsch SK, **Dudek AZ**, Blazar BR, Panoskaltis-Mortari A. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clin Immunol. 2005 Nov;117(2):144-51.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
- Impact Factor: 4.034 Citation Index: 16
117. Nesselova IV, Sham Y, **Dudek AZ**, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. PF4 and IL8 CXC-chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005 Feb 11;280(6):4848-58. URL: <http://www.jbc.org/content/280/6/4948.long>
ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
- Impact Factor: 4.258 Citation Index: 35
118. **Dudek AZ**, Leśniewski – Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot Phase II Study of Gemcitabine and Vinorelbine in Patients with Recurrent or Refractory Small Cell Lung Cancer. Lung. 2005 Jan-Feb;183(1):43-52.
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
- Impact Factor: 2.000 Citation Index: 1
119. **Dudek AZ**, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis Obliterans In Recipients Of Bone Marrow Transplantation: Analysis of Risk Factors And Treatment Outcomes. Biol Blood Bone Marrow Transpl. 2003 Oct;9(10):657-66. URL: [http://www.bbmt.org/article/S1083-8791\(03\)00242-8/fulltext](http://www.bbmt.org/article/S1083-8791(03)00242-8/fulltext)
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
- Impact Factor: 3.300 Citation Index: 128
120. **Dudek AZ**, Pawlak WZ, Kirstein MN. Molecular Targets in the Inhibition of Angiogenesis. Expert Opin Ther Targets. 2003 Aug;7(4):527-41.
ROLE: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
- Impact Factor: 4.798 Citation Index: 11
121. **Dudek AZ**, Nesselova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet Factor 4 Promotes Adhesion of Hematopoietic Progenitors Cells And Binds Interleukin 8: Novel Mechanisms of Modulation of Hematopoiesis. Blood. 2003 Jun 15;101(12):4687-94. URL: <http://www.bloodjournal.org/content/101/12/4687.long?sso-checked=true>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
- Impact Factor: 11.847 Citation Index: 57
122. Reyes M, **Dudek A**, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2003 Feb;109:337-46.
ROLE: Defined intellectual content, Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
- Impact Factor: 12.575 Citation Index: 722
123. Rocha-Lima CM, Savarese D, Bruckner H, **Dudek A**, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

- Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients with Previously Untreated Advanced Pancreatic Cancer. *J Clin Oncol.* 2002 Mar 1; 120(5):1182-91.
ROLE: Conducted experimental studies, Data acquisition, Manuscript editing, Manuscript review.
Impact Factor: 20.982 Citation Index: 90
124. Gupta P, Oegema T, Brazil J, **Dudek A**, Slungaard A, Verfaillie C. Human LTC-IC Can Be Maintained For At Least 5 Weeks In Vitro When Interleukin-3 And A Single Chemokine Are Combined With O-sulfated Heparan Sulfates: Requirement For Optimal Binding Interactions Of Heparan Sulfate With Early-Acting Cytokines And Matrix Proteins. *Blood.* 2000 Jan 1;95(1):147-55. URL: <http://www.bloodjournal.org/content/95/1/147.long>
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 11.847 Citation Index: 67
125. Gupta P, Oegema, TR Jr, Brazil JJ, **Dudek AZ**, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. *Blood.* 1998 Dec 15;92(12):4641-51. URL: <http://www.bloodjournal.org/content/92/12/4641.long>
ROLE: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 11.847 Citation Index: 108
126. **Dudek AZ**, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet Factor 4 Binds To Glycanated Forms of Thrombomodulin and To Protein C; A Potential Mechanism for Enhancing a Generation of Activated Protein C. *J Biol Chem.* 1997 Dec 12;272(50):31785-92. URL: <http://www.jbc.org/content/272/50/31785.long>
ROLE: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review.
Impact Factor: 4.258 Citation Index: 39

Editorials

1. Dudek AZ, Gupta K, Ramakrishnan S, Mukhopadhyay D. Tumor Angiogenesis 2012. *J Oncol.* 2012:article ID,857383. <http://dx.doi.org/10.1155/2012/857383>

Book Chapters

1. M.N. Kirstein, **A.Z. Dudek**. Review of Selected Patents for Cancer Therapy Targeting. In: *Tumor Angiogenesis Frontiers in Anti-Cancer Drug Discovery Volume 1* eISBN: 978-1-60805-161-8 pp.741-757 (17) doi: 10.2174/978160805161811001010741. *ROLE: Guarantor of integrity of entire study, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.*
2. **Dudek AZ**. Treatment of Metastatic Cancer. In: Devita, Hellman and Rosenberg's Cancer Review. Govindan, R. Hagerstwon: Lippincott Williams & Wilkins, 2009.

Presentations

Invited Oral Presentations at International Professional Meetings, Conferences, etc.

1. Advances in Cancer Immunotherapy “Basic Principles of Cancer Immunotherapy” Society for Immunotherapy of Cancer” Minneapolis, MN, 10/27/2018. Program organizer.
2. International Symposium on Malignant Mesothelioma. Lecture: ”Novel Strategies for Treatment of Mesothelioma after Failure of Front Line Therapy”, Minneapolis, MN, June 8th, 2018
3. Donald Gleason Conference on Prostate and Urologic Cancers. Lecture: “Immunotherapy of Kidney Cancer: The New Old Frontier” University of Minnesota, Minneapolis, MN, November 3rd, 2017.
4. “Best of ASCO 2016” Lectures : Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics, Immunotherapy, Melanoma. September 9-10, 2016, Peru
5. “Recent Advances in Management of Pancreatic Cancer” International Conference on Advances in Hematology and Oncology, August 28-19, 2015 Coeur d’Alene, Idaho
6. “Personalized management of lung cancer?” 13th Uruguayan Congress of Oncology, Montevideo, Uruguay, 22 November 2014
7. “Does immunotherapy bring a new era in treatment of lung cancer?” 13th Uruguayan Congress of Oncology, Montevideo, Uruguay, 22 November 2014
8. “Role of Transcription Factor FoxM1 and Tumor Suppressor ARF in Malignant Melanoma” 9th International Conference of Anticancer Research, Porto Carras, Greece, October 7-11, 2014
9. “Melanoma and Glioblastoma Multiforme 2011 ASCO Abstracts,” Best of ASCO Ecuador-2011, Salinas, Ecuador, 07/29-30/2011.
10. “A phase II study of dasatinib in patients with previously treated malignant mesothelioma: CALGB 30601,” International Mesothelioma Interest Group 2010, Kyoto, Japan, 08/31-9/3/2010.
11. "Large Multivalent Immunogen Vaccine in Patients with Metastatic Melanoma" and "Blood Outgrowth Endothelial Cell-based Delivery of Cancer Gene Therapy," 8th International Conference of Anticancer Research, Kos, Greece, 10/17-22/2008.
12. “Outcome of High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: Single Institution Experience,” 33rd ESMO Congress, Stockholm, Sweden, 09/12-16/2008.
13. “Outcome of High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: Single Institution Experience,” 33rd ESMO Congress, Stockholm, Sweden, 09/12-16/2008.
14. “Prognostic Significance of Molecular and Clinical Factors in Stage IB NSCLC: A Laboratory Companion Study to CALGB 9633,” 12th World Conference on Lung Cancer, Seoul, South Korea, 09/2-6/2007.
15. “Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC),” ESMO Conference (ECLU), Lugano, Switzerland, 07/5-8/2007.

16. "Biweekly Pemetrexed and Gemcitabine in Patients with Advanced Solid Tumors," 3rd European Spring Oncology Conference, Marbella, Malaga, Spain, 6/16-18/2005.
17. "Bronchiolitis Obliterans after Bone Marrow Transplantation," Polish Society of Hematology Meeting, Warsaw, Poland, 11/1999.

Invited Oral Presentations at National Professional Meetings, Conferences, etc.

1. "New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice," Iowa City, IA, 9/2006.
2. "Reducing Toxicities Associated with Treatment of Gastrointestinal Malignancies," Cytoprotection Institute for Education: Curriculum Workshop, Chicago, IL, 4/2006.
3. "Second Line Chemotherapy for Advanced Non-Small Cell Lung Cancer," Current Trends in Lung, Head and Neck Meeting, Detroit, MI, 4/2006.
4. "Modern Management of Non-Small Cell Lung Cancer," University of South Dakota, 11/2005.
5. "Novel Therapies of Lung Cancer," Mayo Clinic Lung Cancer Symposium, Rochester, MN, 4/2004.
6. "New Developments in the Treatment of Colorectal Cancer," The University of Texas, MD Anderson Cancer Center, Houston, Texas, 12/2003.
7. "The Impact of EGFR-TK Inhibition on Non-Small Cell Lung Cancer," University of South Dakota, Sioux Falls, SD, 11/2003.

Invited Oral Presentations at Local and Regional Professional Meetings, Conferences, etc.

1. "Tailoring Oncology Care with Genomics" Department of Medicine Grand Rounds, University of Illinois, 5/28/2013
2. "Individualized Medicine-Tailoring Patient Care with Genomic Profiling of Melanoma", 3rd Biennial Melanoma Patient Education Symposium, Mayo Clinic, Rochester, MN, 5/18/2013.
3. "Management of Early Stage Non-Small Cell Lung Cancer," Internal Medicine Review and Update 2009, University of Minnesota, 11/12/2009.
4. "Management of Advanced Lung Cancer," Hennepin Medical Center, Minneapolis, Minnesota, 3/13/2008.
5. "Management of Advanced Malignant Melanoma," Department of Dermatology Grand Rounds, University of Minnesota, 1/9/2008.
6. "Targeted therapy in Ovarian Carcinoma," Division of Gynecologic Oncology Consensus Conference, University of Minnesota, 5/2007.
7. "Diagnosis Imaging and Treatment of C.N.S. Tumors," Internal Medicine Residency Core Conference, University of Minnesota, 12/2006.
8. "Management of Invasive and Metastatic Bladder Cancer," Urology Core Curriculum, University of Minnesota, 12/2006.
9. "Novel Gemcitabine Doublets in NSCLC Treatment," Novel Therapies in Thoracic Oncology, University of Minnesota, 11/2006.
10. "Malignant Pleural Mesothelioma," University of Minnesota, 10/2006.
11. "Modern Management of Kidney Cancer," University of Minnesota, 3/2006.
12. "Thoracic Oncology and Primary Care," University of Minnesota, 11/2005.

13. "Lung Cancer," Thoracic Oncology Conference, University of Minnesota, 10/2004.
14. "Hematopoietic Growth Factors: Indications and Use Guidelines," Internal Medicine Review & Update 2004, University of Minnesota, 10/2004.
15. "Novel Therapies in Thoracic Oncology," University of Minnesota, 9/2003.
16. "Thoracic Oncology and Primary Care," University of Minnesota, 3/2003.
17. "Novel Therapies in Thoracic Oncology," University of Minnesota, 10/2002.
18. "Family Practice Review: Screening for Lung Cancer," University of Minnesota, 5/2001.

Published Abstracts

1. Figlin R. A., Nicolette C. A., Amin A., **Dudek A.**, Logan T., Lance R. S., Holzbeierlein J. M., Pal S. K., Master V. A., DeBenedette M., Tcherepanova I.Y., Jain R., Williams W. L., Miesowicz F., Monesmith T. Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. *J Clin Oncol.* 29: 2011 (suppl; abstr 2532)
2. Danesi H., **Dudek A.**, Spindler E., Alcorn Jr H.. Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel. *J Clin Oncol.* 29: 2011 (suppl; abstr e13059)
3. Ding L., Bliss R. L., Ingebrand M., Allen T., Ives P., **Dudek A.**, Kratzke R. A. Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria. *J Clin Oncol.* 29: 2011 (suppl; abstr 10593)
4. Powell S. F., Beitinjaneh A., Bliss R. L., Kratzke R. A., Leach J. W., **Dudek A.** Phase II study of topotecan and bevacizumab in advanced refractory non-small cell lung cancer (NSCLC). *J Clin Oncol.* 29: 2011 (suppl; abstr 7563)
5. Zwolak P., Borja-Cacho D., Phillips P., Dudeja V., Dawra R. K., Talukdar R., Chugh R. K., **Dudek A. Z.**, Vickers S. M., Saluja A. K.. Myricetin a novel natural antineoplastic agent decreases progression of human pancreatic cancer via inhibition of akt kinase and erk pathways. Abstract #: 558, 3rd Annual Academic Surgical Congress, February 13-15,2008, Huntington Beach, CA
6. **Dudek AZ**, Lesniewski-Kmak K, Koca N., Chereddy S., Maddaus, M, Dhlber P. Kratzke, R. Phase II Trial of Neoadjuvant Therapy with Carboplatin and Gemcitabine with Thalidomide in Patients with Stage IIB and IIIA Non-Small Cell Lung Cancer. 2007 ESMO Conference Lugano, Switzerland
7. Ready N, **Dudek AZ**, Wang XF, Graziano S, Green MR, Vokes EE. CALGB 30306: A phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive stage small cell lung cancer. 2007 ASCO Annual Meeting Proceedings. Abstract 7563.
8. **Dudek AZ**, Gada P, Mullamala K, Shehadeh N. Phase I study of bortezomib plus cetuximab in patients with tumors expressing epidermal growth factor receptor. 2007 ASCO Annual Meeting Proceedings. Abstract 18143.
9. Dham A, **Dudek AZ**. Sequential Therapy with Sorafenib and Sunitinib in Renal Cell Carcinoma. 2007 ASCO Annual Meeting Proceedings. Abstract 5106.
10. Zwolak P, Manivel C, Jasinski P, Fisher J, Kirstein MN, **Dudek AZ**, Cheng EY. Zoledronic acid release from polymethylmethacrylate carrier and in vitro activity against giant cell tumor of bone. MSTs Meeting; November 10, 2006; Italy.
11. Zwolak P, Jasinski P, Farassati F, Thalhammer T, **Dudek AZ**. Selective protein kinase C- β inhibitor (Enzastaurin) suppresses tumor growth, bone osteolysis, cancer -induced bone pain, and enhance radiosensitivity of the bone tumor. AACR Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment, September 12-15, 2006; Chicago, IL
12. **Dudek AZ**, Larson T, McCleod M, Schneider DJ, Dowell JE, Ye Z, Cunneen J, Monberg M, Tai F, Obasaju CK. Initial results of a phase II study of biweekly pemetrexed and

- gemcitabine in patients with advanced NSCLC. *J Clin Oncol.*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7128.
13. Jahan TM, Gu L, Wang X, Kratzke RA, **Dudek AZ**, Green MR, Vokes EE, Kindler HL. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). *J Clin Oncol.*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7081.
 14. Mekhail T, Serwatowski P, **Dudek AZ**, Belani C, Jankowska R, Pandya KJ, Arnold S, Brahmer J, Gitlitz B, Govindan R. A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. *J Clin Oncol.*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7098.
 15. Kumar P, Keshtgarpour M, Kumar H, **Dudek AZ**. A phase I clinical study of biweekly carboplatin and gemcitabine in patients with advanced solid tumors. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 12024.
 16. **Dudek AZ**, Math V, Mescher M, Miller, J. Autologous large multivalent immunogen vaccine for the treatment of stage IV malignant melanoma and stage IV renal cell carcinoma. *Proceedings of the ECCO*, Abstract #513, 2005.
 17. **Dudek AZ**, Yunis C, Kumar S, Harrison, L, Hawkinson R, Miller J. Immune Response Activation With a Toll-like Receptor 7 Agonist: Results of a Phase 1 Study. *Meeting Proceedings of the ASCO*, Abstract #2515, 2005.
 18. Zwolak P, Goblirsch M, Nelson C, Clohisy DR, **Dudek AZ**. Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain.” *J Bone Mineral Res.* 20: P27-P28 Suppl. 2, 2005.
 19. Zwolak P, Goblirsch P, Nelson N, Clohisy DR, **Dudek AZ**. Anti-angiogenic therapy and local irradiation exhibit additive effects in decreasing tumor burden and reducing bone cancer pain. “Skeletal Complications of Malignancy” Meeting in Bethesda, April 28-30, 2005.
 20. **Dudek AZ**, Griffin R, Nelson CM, Ghandi L, Terai K, Ugaz E, Galvez J. Preclinical Evaluation of MT103, a postulated novel protein kinase C modulator: Validation of drug discovery methods based on molecular topology. *Proceedings of the AACR*, Abstract #3963, 2005.
 21. Zwolak P, Nelson C, Goblirsch M, Clohisy DR. **Dudek AZ**. Therapy with antibody to VEGF in combination with megavoltage irradiation improves control of metastatic renal cell carcinoma of bone. Immune, vascular and gene targeting for cancer imaging and therapy- Meeting, San Diego, Feb. 28 - Mar. 2, 2005.
 22. **Dudek AZ**, Bodempudi V, Nelson C, Chang L, Hebbel RP. Blood Outgrowth Endothelial Cells (BOEC) Contribute to Tumor Vascularization and Can Be Used for Delivery of Cancer Gene Therapy. *Blood.* 104(11):867a, Abstract #3173, 2004.
 23. **Dudek A**, Marker P, Botner D, Hagen D, Chang L, Hebbel R. Anti-Angiogenic Therapy Delivered By Blood Outgrowth Endothelial Cells Reduces Tumor Vessel Number In Mice With Lewis Lung Carcinoma. *Proceedings of the AACR*, 2002.
 24. **Dudek A**, Mahaseth H. Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels Change After Chemotherapy In Non-Small Cell Lung Cancer Patients- Correlation with Tumor Response, Number Of Platelets, And Leukocytes. *Proceedings of the AACR*, 2002.

TEACHING AND CURRICULUM DEVELOPMENT

University of Illinois

2015-ongoing- College of Pharmacy BPS 539, Rotation Instructor
2014 –ongoing- College of Medicine Essential Technologies and Approaches in Translational Research
2014-ongoing- College of Pharmacy Colloquium BPS 385, Rockford
2014-ongoing- College of Pharmacy BPS/MDCH/PMPG 553, Chicago and Rockford

University of Minnesota

Curriculum Development

Ongoing, annual - Lectures, Department of Medicine (DOM) Grand Rounds, DOM Research Conferences,
1998-2012 Garibaldi (HOT Division research) Conferences
1998-2012 Radiation Oncology Residency Program Lectures “Lung Cancer”
2011-2012 Educational Curriculum Lectures for the Oncology Resident Elective “Lung Cancer”
2010 and 2011, MICa 8005 and 8013 class “Translational Cancer Research” lecturer. Title: “Phase I clinical trials and experimental therapeutics”
3/24/2010 Gynecological Oncology Fellowship Program “Female Genital Tract Melanoma”
2006 – Oncology Fellowship “Phase I and Phase II Clinical Trials”
2006 - Gynecology Residency Program “Phase I and Phase II Clinical Trials”
2006 – Dermatology Residency Program “Malignant Melanoma”
1998-2006 – Internal Medicine Residency Program, University of Minnesota, Oncology Lectures “Lung Cancer”
1998-2006– Oncology Fellowship, University of Minnesota, Oncology Lectures “Malignant Melanoma”, “Kidney Cancer” and “Lung Cancer”
Thoracic Tumor Conference (weekly)
Malignant Melanoma Conference (monthly)

ADVISING AND MENTORING

Graduate Student Activities

Masters’ students

2010-2012–Javaid Sehrish, Master thesis, Oral Biology Program, Dental School, University of Minnesota.
Title: Molecular Abnormalities in Mucosal Melanoma.

2010 – Emily Craig Zabor, Master thesis, Biostatistics Plan B Committee, Division of Biostatistics, University of Minnesota.
Title: Adaptive Controlled Dose Escalation with Multiple Individual Covariates for Phase I Clinical Trials.

2010 – Ming Chi, Master’s thesis, School of Public Health, University of Minnesota.
Title: Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials.

PhD students

2008-2012 – Math Thumbigere, PhD thesis, Oral Biology Program, Dental School, University of Minnesota.

Title: Bisphosphonate-Related Osteonecrosis of the Jaw. Currently postdoctoral fellow in Martha Somerman laboratory at NIH (NIDCR).

2009-2011 – Ali Khammanivong, PhD thesis, Oral Biology Program, Dental School, University of Minnesota.

Title: Regulatory Roles of Calprotectin in Head and Neck Squamous Cell Carcinogenesis.

2006-2010 – Peter Jasinski, Master thesis, University of Vienna, Austria.

Title: Protein kinase C as a Target for Cancer Therapy.

PhD thesis, Military Medical Institute, Warsaw, Poland.

Title: Preclinical Evaluation of Anti-cancer Activity of Novel Multi-Kinase Inhibitor.

2005-2007 – Tomasz Arodz, PhD thesis, University of Science and Technology, Cracow, Poland.

Title: Attention-shifting Strategies for Ensemble Pattern Recognition in Cancer Detection and Treatment Discovery.

Professional Student Activities

2014 – 2016 Hiral Shah, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research. Currently, Assistant Professor, Loyola University, Chicago

2013 – Stanley Borowicz, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research.

2013 – Rozina Chowdhery, Oncology Fellow, Department of Medicine, University of Illinois.

Title: Clinical Cancer Research.

2012-2013 – Chul Kim, Internal Medicine Resident,, Department of Medicine, University of Minnesota. Title: Clinical Cancer Research. Currently, Assistant Professor, Georgetown University.

2012-2013 – Tulasi Gummadi, Oncology Fellow, Department of Medicine, University of Minnesota.

Title: Clinical Cancer Research.

2006-2013 – Steven Powell, Internal Medicine Resident, Oncology Fellow, Department of Medicine, University of Minnesota. Title: Clinical Cancer Research. Currently, Assistant Professor, University of South Dakota

2009-2012 – Dylan Zylla, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.

Title: Clinical Cancer Research.

2008-2011 – Satya Bommakanti, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.

Title: Clinical Cancer Research.

2008-2009 – Amer Beitinjaneh, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota. (Private Practice)
Title: Phase II Study of Bevacizumab and Topotecan in NSCLC.

2004-2009 – Priya Kumar, Oncology Fellow, Adjunct Faculty (Community Physician), Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2006-2007 – Purvi Gada, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota. (Adjunct Faculty - Community Physician, U of M)
Title: Clinical Cancer Research.

2006-2007 – Anu Dham, Oncology Fellow, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

2005-2007 – Nauman Moazzam, Oncology Fellow, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota.
Title: Clinical Cancer Research.

Post-doctoral fellows supervised

2009-2010 – Andrew Stein, Postdoctoral Fellow, the Institute for Mathematics and its Applications, University of Minnesota.
Title: Mathematical Models of Tumor Response and Disease Survival.

2004-2009 – Paul Zwolak, Postdoctoral Research Associate, University of Minnesota
PhD thesis, Military Medical Institute, Warsaw, Poland
Title: Anti-tumoral Effect of Combined Radiation and Tyrosine Kinase Inhibitor in Model of Breast Cancer Metastases to Bone.

1999-2006 – Hemchandra Mahaseth, Postdoctoral Research Associate, University of Minnesota
Title: Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer.

Residents Supervised

2014 – Rohan Sharma, Internal Medicine Resident, Internal Medicine Advisor
2010 – Bryan Trottier, Internal Medicine Resident, Internal Medicine Advisor
2009 – Saqub Razaque, Internal Medicine Resident, Internal Medicine Advisor

Other Mentoring Activities

Phase I, II Protocol Development Writing (2015-2016)

Sharad Khurana, Internal Medicine Resident, Stroger Hospital
Sujay Shah, Internal Medicine Resident, UIC
Jun Choi, Internal Medicine Resident, UIC

Sushma Bhardaway, Hospitalist, Stroger Hospital
Ardaman Shergill, 3rd year Hematology/Oncology Fellow, UIC (now in private practice)
Basharath Khan, 2nd year Hematology/Oncology Fellow, UIC
Scott Wirth, PharmD, College of Pharmacy, Clinical Assistant Professor, UIC
Timothy Schmidt, Internal Medicine Resident, UIC
Kunai Desai, 2nd year medical student, UIC
J. Egeria Lin, PhD, 2nd year medical student, UIC
Thomas Bielawiec, 2nd year medical student, UIC
Matthew Durst, PhD, 2nd year medical student, UIC
2014 – Oana Danciu, Oncology Junior Faculty, Department of Medicine, University of Illinois.
Title: Clinical Cancer Research.
2013 – Neeta Venepalli, Oncology Junior Faculty, Department of Medicine, University of Illinois.
Title: Clinical Cancer Research.
2010-2012 - Mentor, Minnesota Craniofacial Research Training Program, University of Minnesota Dental School

CLINICAL SERVICE

Scientific Service

Conferences

9th International Conference of Anticancer Research, Porto Carras, Greece, October 7-11, 2014, Member of Organizing Committee.

UIC College of Medicine
Urban Health Program, Mentor 2014-current

Lung Cancer Session Co-chair Translational Research Approaches to Reduce Health Disparities in Lung Disease University of Illinois, 9/10-11/2012.

UIC College of Medicine
Clinical Colloquium “Cancer Therapy Selected Clinical Cases”

Research Groups

2013-present Co-leader, Cancer Target and Therapeutics Program
University of Illinois Cancer Center
2012 Co-leader, Tumor Microenvironment
Masonic Cancer Center, University of Minnesota, School of Medicine
2011 – present Respiratory Committee, Member, Alliance
2011 – present Chair, Scientific Review Committee, Midwest Melanoma Partnership
2006 – 2012 Senior Member, Oral Biology Program, School of Dentistry, University of Minnesota.
2003 - 2012 Member, Vascular Biology Program, Department of Medicine, University of Minnesota
2003 - 2012 Leader, Phase 1 Team, Solid Tumor Oncology, CETI, Masonic Cancer Center,
University of Minnesota
2003 - 2012 Co-Leader, Interdisciplinary Tumor Site Team for Melanoma, University of Minnesota
2009 - 2011 Member, Tumor Biology Program, University of Minnesota
2009 – 2011 Respiratory Committee, Cadre Member, Cancer and Leukemia Group B

Editorships/Journal Reviewer Experience***Editorial Boards***

- 2010 and 2011 Invited Guest Editor, Special Issue Tumor Angiogenesis, Journal of Oncology
 2007- present Editorial Board Member, The Open Cancer Journal
 2006 - present Editorial Advisory Board member, Recent Patents on Anti-Cancer Drug Discovery

Ad Hoc Reviewer of Manuscripts

- 2014-present Clinical Cancer Research
 2010 - 2012 Journal of Thoracic Oncology
 2010 Annals of Oncology
 2010 Investigational New Drugs
- 2008 - 2011 Blood
 2006 - 2011 Translational Research
 2005 - 2011 The American Journal of Clinical Oncology
 2008 - 2009 The American Journal of Pathology
 2008 - 2009 British Journal of Cancer
 2005 - 2009 Cancer Letter
 2008 Gene Therapy
 2007 Archives of Medical Research
 2007 Acta Oncologica
 2007 Journal of Clinical Oncology
 2007 Cancer Chemotherapy and Pharmacology
 2007 Cancer Immunology Immunotherapy
 2005 - 2007 European Respiratory Journal
 2006 American Journal of Physiology
 2006 Cancer Causes and Control
 2006 Mayo Clinic Proceedings
 2006 The Journal of Laboratory and Clinical Medicine
 2006 Oncology
 2006 Combinatorial Chemistry & High Throughput Screening
 2005 - 2006 Lung
 2005 - 2006 The American Journal of Hematology
 2005 - 2006 European Respiratory Journal

Review panels for external funding agencies, foundations, etc.***Invited Reviewer of National and International Grant Applications***

- 2014 CDMRP Lung Cancer Concept Award
 2013 CDMRP LCRP Clinical Exploration panel, chairman
 2012 CDMRP Breast Cancer Clinical Translational Research Award
 2011 James & Esther King Biomedical Research Program and the Bankhead-Coley Cancer Research Program, Florida Department of Health
 2010 CDMRP BCRP Pathobiology
 2010 CDMRP Lung Cancer Promising Clinician
 2010 James & Esther King Biomedical Research Program and the Bankhead-Coley Cancer Research Program, Florida Department of Health
 2009 CDMRP BCRP Pathobiology
 2009 CDMRP PRMRP09 Mesothelioma Panel
 2009 Hungarian Scientific Research Fund (OTKA)

Committee memberships

Committee and administrative work – National

- 2013 - present Steering Committee Member, Big Ten Cancer Research Consortium
- 2012 - present Co-Chair, Thoracic Oncology Working Group, Big Ten Cancer Research Consortium
- 2012 - present Alliance Respiratory Committee Member
- 2011 - present Chair, Scientific Review Committee, Midwest Melanoma Partnership
- 2006 - present Pancreatic Cancer Research Team Member,
- 2006 - 2011 Cancer and Leukemia Group B, Respiratory Committee Cadre Member

Service to the University/Medical School/Department

University of Minnesota

Medical School Service and Intercollegiate Service

Academic Health Center

- 1998 - 2012 Co-Chair, Thoracic Oncology Program, University of Minnesota Comprehensive Cancer Center
- 2010 – 2011 University of Minnesota Data Safety Monitoring Board member
- 2008 – 2011 University of Minnesota, Institutional Review Board member
- 2008 Ad Hoc protocol reviewer University of Minnesota GCRC
- 2005 Academic Health Center Research Service Organization Search Committee

Medical School

- 2007 Conflict of Interest Task Force, University of Minnesota
- 2006-2007 Radiation Oncology Development Committee, University of Minnesota
- 2006 Cancer Care Committee, University of Minnesota

Department/Unit Service

Division of Hematology, Oncology, and Transplantation

- 2005 - 2012 Division of Hematology, Oncology, and Transplantation Fellowship Committee
- 2005 - 2008 Director, Clinical Research; monthly meetings with University of Minnesota Cancer Center Clinical Trial Office staff regarding on-going clinical trials for treatment of cancer and patient accrual to these studies.

Masonic Cancer Center

- 2012 Member, Executive Committee, University of Minnesota, Masonic Cancer Center, University of Minnesota
- 2008 - 2012 – Leader, Solid Tumor Team, Cancer Experimental Therapeutics Initiative, Masonic Cancer Center, University of Minnesota

Community Outreach Activities

- 2013, April 16th, UI Cancer Center Outreach, Simeon Career Academy Visit to educate students on cancer research as a field of profession
- 2013, September 13th, Bridging the Gap: Emerging Health Issue in Underrepresented Minorities. “Lung Cancer in Minorities”
- 2011 - 2012 Speaker: Kidney Cancer Association
- 2011, June 20th Speaker: Bladder and Kidney Cancer Patient Education
- 2010, September 24th Speaker: Midwest Melanoma Symposium

Prepared: 4.29.2019

2010, September 19th Speaker: Lungevity 5K Walk/Run

2009 - 2016 Member, Academic Advisory Committee, Health, Technology, Innovation, Illinois
Medical District

2009 - present Member, Board of Directors: A Breath of Hope Lung Foundation.

Updated: 02.07.2018